Uterine Neoplasia (Leiomyoma, Leiomyosarcoma)

Uterine neoplasia encompasses benign and malignant tumors arising from the smooth muscle layers of the myometrium, with leiomyoma (fibroid) being the most common benign tumor and leiomyosarcoma the malignant counterpart. These tumors occur predominantly in middle-aged to older intact female dogs and, less commonly, in cats. Leiomyomas are well-circumscribed, slow-growing, hormone-dependent tumors that often remain asymptomatic, whereas leiomyosarcomas are locally invasive, potentially metastatic, and may cause significant clinical signs. The tumors can arise in any part of the uterine body or horns, and their growth is influenced by ovarian steroid hormones, particularly progesterone and estrogen. In the context of theriogenology, uterine neoplasia must be differentiated from other uterine pathologies such as cystic endometrial hyperplasia, pyometra, and pregnancy, as clinical signs may overlap. Definitive diagnosis requires histopathology, and treatment typically involves surgical excision (ovariohysterectomy) with a favorable prognosis for benign tumors and a guarded prognosis for malignant ones.

The exact etiology of uterine smooth muscle tumors is not fully understood, but hormonal factors play a pivotal role. Progesterone and estrogen receptors are expressed in both leiomyomas and leiomyosarcomas, and tumor growth is often stimulated by endogenous ovarian hormones during estrous cycles. Chronic exposure to progestins, either endogenous (repeated estrous cycles) or exogenous (e.g., progestin-based contraceptives), may increase the risk. Genetic mutations, such as alterations in tumor suppressor genes (e.g., p53) and oncogenes (e.g., c-Kit), have been implicated in malignant transformation. In dogs, leiomyomas are more common in older, intact bitches, suggesting cumulative hormonal exposure. In cats, uterine neoplasia is rare, but when present, it may be associated with ovarian remnants or hormonal imbalances. No infectious agents have been consistently linked to uterine smooth muscle tumors. Additionally, chronic inflammation or trauma to the uterus may predispose to neoplastic transformation, though evidence is limited.

Uterine neoplasia is uncommon in dogs and cats compared to other reproductive tumors (e.g., mammary tumors). Leiomyomas are the most frequent uterine tumor in dogs, accounting for 85-90% of all uterine neoplasms, with a mean age of onset around 10-12 years. Breeds such as Boxers, German Shepherds, and Golden Retrievers may be overrepresented, but no strong breed predisposition is established. Leiomyosarcomas are rare, comprising less than 10% of uterine tumors, and occur in slightly older dogs (mean 11-14 years). Intact females are almost exclusively affected, as neutering before puberty significantly reduces the risk. In cats, uterine neoplasia is exceedingly rare, with leiomyomas and leiomyosarcomas reported sporadically, often in older queens (mean 10-15 years). Parity does not appear to influence risk, but nulliparous animals may have a slightly higher incidence. The prevalence in the general canine population is estimated at 0.3-0.5% based on necropsy studies, but clinical cases are less frequent due to asymptomatic nature.

Leiomyomas arise from the smooth muscle cells of the myometrium. They are typically well-circumscribed, encapsulated, and composed of interlacing bundles of spindle-shaped smooth muscle cells with minimal mitotic activity. Their growth is hormone-dependent, with estrogen and progesterone receptors mediating cellular proliferation. During proestrus and estrus, elevated estrogen levels may stimulate tumor growth, while progesterone during diestrus promotes further expansion. In contrast, leiomyosarcomas are malignant tumors with increased cellular atypia, high mitotic index, and invasive growth into surrounding myometrium and uterine wall. They can metastasize hematogenously to the lungs, liver, and regional lymph nodes. The pathophysiology of clinical signs involves mass effect, uterine distortion, and potential obstruction of the uterine lumen, leading to secondary complications such as hydrometra, pyometra, or torsion. In some cases, tumor necrosis or ulceration may cause vaginal bleeding. Hormonal receptors in malignant tumors may be downregulated, making them less responsive to hormonal manipulation.

Intrinsic factors include age (older intact females), breed (possible genetic predisposition in certain lines), nulliparity, and hormonal imbalances such as prolonged estrogen or progesterone exposure. Endogenous factors include repeated estrous cycles without pregnancy, which lead to cumulative hormonal stimulation. Extrinsic factors include administration of exogenous progestins (e.g., megestrol acetate for estrus suppression) or estrogens (e.g., diethylstilbestrol for mismating), which may increase the risk of tumor development. Obesity and high-fat diets have been suggested as risk factors in some studies, though evidence is inconclusive. In cats, ovarian remnant syndrome after ovariohysterectomy can lead to persistent hormonal stimulation and potentially increase the risk of uterine stump neoplasia, though this is rare. Environmental factors such as exposure to endocrine-disrupting chemicals may also play a role, but data are lacking.

Clinical signs depend on tumor size, location, and malignancy. Many leiomyomas are incidental findings during ovariohysterectomy or necropsy, as they often cause no clinical signs. When signs occur, they may include vaginal discharge (serous, hemorrhagic, or mucoid), abdominal distension, and palpable abdominal mass. Large tumors may cause tenesmus, dysuria, or constipation due to compression of adjacent organs. In cases of leiomyosarcoma, signs are more severe and may include lethargy, anorexia, weight loss, and signs of systemic illness. Hemorrhage into the abdominal cavity or uterine lumen can lead to anemia and weakness. If the tumor obstructs the uterine lumen, fluid accumulation (hydrometra or pyometra) may occur, leading to purulent discharge and signs of sepsis. In rare cases, uterine torsion or rupture can cause acute abdomen. On physical examination, a firm, nodular uterine mass may be palpated in the caudal abdomen, but this is often difficult in obese or large dogs.

Differential diagnoses include: 1) Pyometra: presents with purulent vaginal discharge, polyuria/polydipsia, and systemic signs; ultrasonography shows fluid-filled uterus with thickened walls; cytology shows degenerate neutrophils and bacteria. 2) Cystic endometrial hyperplasia (CEH): often coexists with pyometra; ultrasonography shows multiple anechoic cysts in the endometrium; histopathology confirms. 3) Pregnancy: history of mating, fetal heartbeats on ultrasound, and fetal mineralization on radiographs after day 45. 4) Uterine torsion: acute abdomen, shock, and rapid deterioration; imaging may show a twisted uterine pedicle. 5) Vaginal neoplasia (e.g., leiomyoma, fibroma): mass in the vaginal canal, visible on vaginoscopy or digital examination. 6) Ovarian neoplasia: may present with abdominal mass and hormonal signs; ultrasonography shows ovarian enlargement. 7) Abdominal lymphadenopathy or other abdominal masses (e.g., splenic mass) may mimic uterine tumors on palpation. 8) Endometritis: chronic inflammation with vaginal discharge; cytology and culture help differentiate. 9) Foreign body or uterine stump granuloma: history of ovariohysterectomy. 10) Uterine prolapse: rare, but may present as a mass protruding from the vulva.

The diagnostic approach begins with a thorough history and physical examination, including abdominal palpation. If a uterine mass is suspected, the following steps are recommended: 1) Complete blood count, serum biochemistry, and urinalysis to assess systemic health and rule out concurrent disease. 2) Abdominal ultrasonography is the primary imaging modality; it can identify uterine masses, assess their echogenicity, size, and invasiveness, and evaluate other abdominal organs for metastasis. 3) Thoracic radiographs are indicated if malignancy is suspected to check for pulmonary metastases. 4) Vaginal cytology may be performed to evaluate the estrous cycle stage and rule out vaginitis. 5) If the mass is accessible, fine-needle aspiration and cytology may be attempted, but this is often inconclusive for smooth muscle tumors. 6) Definitive diagnosis requires histopathology after surgical excision (ovariohysterectomy). 7) Immunohistochemistry (e.g., smooth muscle actin, desmin) can confirm the smooth muscle origin. 8) In cases where surgery is not immediately performed, serial ultrasonography can monitor tumor growth, but biopsy is not recommended due to risk of hemorrhage and seeding.

Hematology may be normal in benign cases, but in malignant or complicated cases, findings may include anemia (due to chronic blood loss), leukocytosis with a left shift (if secondary infection or necrosis), and thrombocytopenia (rare). Serum biochemistry may reveal elevated liver enzymes (if metastasis), azotemia (if dehydration or renal compromise), and hyperglobulinemia (if chronic inflammation). Serum progesterone and estrogen levels are typically within normal ranges for the stage of the estrous cycle, but may be elevated if there is concurrent ovarian pathology. Vaginal cytology reflects the estrous cycle stage; in intact females, it may show cornified epithelial cells during estrus or intermediate/parabasal cells during diestrus. If there is vaginal discharge, cytology may show neutrophils, bacteria, and cellular debris. Uterine culture is not routinely performed unless pyometra is suspected. Histopathology is the gold standard for diagnosis, revealing characteristic features of leiomyoma (well-differentiated smooth muscle cells, low mitotic index) or leiomyosarcoma (cellular atypia, high mitotic index, invasion).

Abdominal ultrasonography is the most valuable imaging modality. Leiomyomas typically appear as well-defined, homogeneous, hypoechoic masses within the uterine wall, often with a whorled appearance. They may be single or multiple, and the uterine wall may be thickened. Leiomyosarcomas may appear more irregular, with heterogeneous echotexture, areas of necrosis or hemorrhage, and invasion into surrounding tissues. Ultrasonography can also detect secondary changes such as hydrometra or pyometra (anechoic or echogenic fluid within the uterine lumen). Color Doppler may show vascularity within the tumor. Thoracic radiographs are essential for staging malignant tumors; pulmonary metastases appear as nodular interstitial patterns. Abdominal radiographs may show a soft tissue mass in the caudal abdomen, but they are less sensitive than ultrasound. Computed tomography (CT) and magnetic resonance imaging (MRI) provide more detailed anatomical information and are useful for surgical planning, especially for large or invasive tumors. Vaginoscopy is not directly useful for uterine tumors but may help rule out vaginal masses.

Fine-needle aspiration of a uterine mass is rarely performed due to the risk of hemorrhage and the difficulty in obtaining diagnostic samples. If attempted, cytology may show spindle-shaped cells with elongated nuclei, but differentiation between benign and malignant is unreliable. Vaginal cytology is useful for staging the estrous cycle but does not diagnose uterine tumors. Histopathology is definitive. Leiomyomas are characterized by well-differentiated smooth muscle cells arranged in interlacing fascicles, with minimal nuclear atypia and low mitotic index (<1 per high-power field). Leiomyosarcomas show increased cellularity, nuclear pleomorphism, hyperchromasia, and a high mitotic index (>10 per high-power field), with evidence of invasion into the myometrium or blood vessels. Immunohistochemistry for smooth muscle actin (SMA) and desmin is positive in both, while vimentin may be positive in malignant tumors. Special stains such as Masson's trichrome can help differentiate smooth muscle from collagen. In cases of metastasis, histopathology of affected organs (e.g., lung) may be performed.

The treatment of choice for uterine neoplasia is surgical excision via ovariohysterectomy (OHE). This removes the tumor and eliminates the source of ovarian hormones, preventing further growth and reducing the risk of recurrence. For benign leiomyomas, OHE is curative, and the prognosis is excellent. For leiomyosarcomas, OHE is also the primary treatment, but additional staging (thoracic radiographs, abdominal ultrasound) is necessary to rule out metastasis. If metastasis is present, chemotherapy may be considered, although there is limited evidence for efficacy. Doxorubicin-based protocols have been used, but response rates are variable. In cases where the tumor is inoperable or the patient is a poor surgical candidate, medical management with hormonal therapy (e.g., GnRH agonists or antagonists, progestin antagonists) may be attempted, but this is not well-documented. Supportive care includes fluid therapy, antibiotics if secondary infection is present, and pain management. In breeding animals, OHE is not an option if fertility is desired; however, uterine tumors can interfere with pregnancy, and surgical removal of the tumor (myomectomy) may be attempted in select cases, but this is rarely performed in veterinary medicine.

The prognosis for benign uterine leiomyomas is excellent after OHE, with no impact on survival. For leiomyosarcomas, the prognosis is guarded to poor, depending on the presence of metastasis at the time of diagnosis. The 1-year survival rate for dogs with leiomyosarcoma is approximately 50%, and the median survival time is around 12-18 months with surgery alone. Factors associated with a worse prognosis include tumor size >5 cm, high mitotic index, vascular invasion, and metastasis. In cats, uterine leiomyosarcoma is rare but carries a similarly guarded prognosis. For breeding animals, the prognosis for future fertility is poor if OHE is performed; if myomectomy is attempted, there is a risk of recurrence and complications during pregnancy. Overall, early detection and surgical intervention improve the prognosis.

After OHE, patients should be monitored for surgical complications (e.g., infection, dehiscence) during the first 2 weeks. For benign tumors, no further follow-up is required beyond routine postoperative care. For malignant tumors, regular monitoring is recommended: thoracic radiographs and abdominal ultrasound every 3-6 months for the first 2 years to detect metastasis. Serum tumor markers are not available. If the patient is intact and myomectomy was performed, serial ultrasonography every 3-6 months is recommended to monitor for recurrence. In breeding animals, a breeding soundness examination should be performed before the next estrus, including vaginal cytology and progesterone assays to time breeding. If the patient is on medical therapy, hormonal levels should be monitored periodically.

Pearls: 1) Uterine leiomyomas are often incidental findings; always submit uterine tissue for histopathology after OHE, even if grossly normal. 2) In older intact bitches with a palpable abdominal mass, consider uterine neoplasia in the differential. 3) Ultrasonography is the best imaging modality; look for a well-defined hypoechoic mass in the uterine wall. 4) OHE is curative for benign tumors and is the treatment of choice for malignant tumors. 5) If a leiomyosarcoma is diagnosed, stage the patient thoroughly for metastasis. Pitfalls: 1) Do not confuse a uterine tumor with a pregnancy; always perform ultrasound to check for fetal heartbeats. 2) Avoid fine-needle aspiration of uterine masses due to risk of hemorrhage and seeding. 3) Do not delay surgery in cases of suspected malignancy; early intervention improves prognosis. 4) Do not assume that a uterine mass is benign based on imaging alone; histopathology is essential. 5) In breeding animals, do not recommend OHE without discussing the impact on fertility; consider alternative options if the tumor is small and the owner desires future breeding.

There are no specific drug protocols for uterine neoplasia. Hormonal therapy is not standard. For malignant tumors, chemotherapy protocols may be considered, but evidence is limited. Doxorubicin (30 mg/m² IV every 3 weeks) is the most commonly used agent, but response rates are low. Carboplatin (300 mg/m² IV every 3 weeks) has also been used. These protocols are based on extrapolation from other soft tissue sarcomas. Supportive care includes antibiotics (e.g., amoxicillin-clavulanate 20 mg/kg PO q12h) if secondary infection is present, and analgesics (e.g., carprofen 2.2 mg/kg PO q12h) for pain. In cases of uterine torsion or rupture, emergency stabilization with fluids and surgery is required. For breeding management, if the tumor is small and the owner desires to breed, surgical removal (myomectomy) may be attempted, but this is not routinely recommended.

Literature on uterine neoplasia in dogs and cats is limited to case reports and retrospective studies. A retrospective study of 100 canine uterine tumors found that leiomyomas were the most common (85%), with a mean age of 10.5 years, and that OHE was curative. Another study reported that leiomyosarcomas had a high metastatic rate (up to 50%) and a median survival of 12 months. In cats, a review of 20 cases found that uterine tumors were rare, with leiomyomas being the most common benign tumor. There are no prospective clinical trials evaluating chemotherapy for uterine leiomyosarcoma. The American College of Theriogenologists and the European Society for Small Animal Reproduction have published guidelines on the management of reproductive tumors, recommending OHE as the standard of care. Overall, the evidence base is weak, and treatment decisions are often based on extrapolation from other species and expert opinion.